Document is current

Article History

Received: 19 August 2024

Accepted: 27 September 2024

First Online: 15 October 2024

Declarations

:

: Richard B. Lipton, MD, serves on the editorial boards of <i>Neurology</i> and <i>Cephalalgia</i> and is a senior advisor for <i>Headache</i>. He has received research support from the National Institutes of Health. He also receives support from the Migraine Research Foundation and the National Headache Foundation. He has reviewed for the National Institute on Aging and National Institute of Neurological Disorders and Stroke; serves as consultant, advisory board member, or has received honoraria or research support from AbbVie, Aeon, Amgen, Biohaven, Dr. Reddy’s Laboratories, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Teva, Vector, and Vedanta Research. He receives royalties from <i>Wolff’s Headache</i>, 8th edition (Oxford University Press, 2009), and Informa. He holds stock or options in Axon, Biohaven, CoolTech, Manistee, and Wizermed. Jessica Ailani, MD, has served as a consultant for AbbVie, Aeon, Amgen, Biohaven, Dr. Reddy, Eli Lilly, GlaxoSmithKline, Gore, Impel, Ipsen, Linpharma, Lundbeck, Merz, Miravo, Nesos, Neurolief, Pfizer, Scilex, Satsuma, Teva, Theranica, and Tonix; received stock options from Ctrl M; provided editorial services to <i>Current Pain and Headache Reports</i>, SELF, and Medscape; and received clinical trial support from AbbVie, Biohaven, Eli Lilly, Parema, Satsuma, and Zosano. Andrew M. Blumenfeld, MD, has served on advisory boards for, consulted for, and/or been a speaker or contributing author for AbbVie, Aeon, Alder, Allergan, Amgen, Axsome, Biohaven, Equinox, Lilly, Lundbeck, Novartis, Revance, Teva, Theranica, and Zosano. He has received grant support from AbbVie and Amgen.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.